Tenaya Therapeutics (TNYA)
0.73
+0.02 (2.82%)
Upcoming Events
Latest Headlines
Tenaya Therapeutics shows positive gene therapy trial results for heart condition
June 3, 2026 7:02 AM - StreetInsider
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym
June 3, 2026 7:00 AM - Globe NewsWire
Tenaya Therapeutics to present MyPEAK-1 trial data June 3
June 2, 2026 4:30 PM - StreetInsider
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
June 2, 2026 4:30 PM - Globe NewsWire
Form 4 Tenaya Therapeutics, For: May 28 Filed by: Williams R Sanders
May 29, 2026 7:30 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: May 28 Filed by: Walsh Jeffrey T.
May 29, 2026 7:29 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: May 28 Filed by: Stehman-Breen Catherine
May 29, 2026 7:28 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: May 28 Filed by: Srivastava Deepak
May 29, 2026 7:13 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: May 28 Filed by: Parschauer Karah Herdman
May 29, 2026 7:10 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: May 28 Filed by: Lee June
May 29, 2026 7:09 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: May 28 Filed by: Burroughs Amy L.
May 29, 2026 7:08 PM - SEC Filing
Form 8-K Tenaya Therapeutics, For: May 27
May 29, 2026 5:05 PM - SEC Filing
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
May 29, 2026 8:00 AM - Globe NewsWire
Form 4 Tenaya Therapeutics, For: May 18 Filed by: Ali Faraz
May 19, 2026 7:10 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: May 18 Filed by: Tingley Whittemore
May 19, 2026 7:09 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: May 18 Filed by: Higa Tomohiro
May 19, 2026 7:07 PM - SEC Filing
Tenaya reports positive interim results for gene therapy trial
May 15, 2026 6:01 AM - StreetInsider
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
May 15, 2026 6:01 AM - Globe NewsWire
Tenaya Therapeutics, Inc. (TNYA) Reports In-Line Q1 EPS
May 6, 2026 5:49 PM - StreetInsider
Form 10-Q Tenaya Therapeutics, For: Mar 31
May 6, 2026 4:25 PM - SEC Filing
Form 8-K Tenaya Therapeutics, For: May 06
May 6, 2026 4:12 PM - SEC Filing
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026 4:05 PM - Globe NewsWire
Tenaya to present TN-401 gene therapy data at ASGCT 2026 meeting
April 27, 2026 8:30 AM - StreetInsider
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
April 27, 2026 8:30 AM - Globe NewsWire
Form ARS Tenaya Therapeutics, For: Dec 31
April 16, 2026 9:15 AM - SEC Filing
Form DEFA14A Tenaya Therapeutics,
April 16, 2026 9:12 AM - SEC Filing
Form DEF 14A Tenaya Therapeutics, For: May 27
April 16, 2026 9:01 AM - SEC Filing
Leerink Partners Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "remains on track to share interim data"
March 12, 2026 10:37 AM - StreetInsider
William Blair Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "entering 2026 with increasing momentum"
March 12, 2026 10:35 AM - StreetInsider
Full Article List
